These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 9142964)
21. Formestane in the treatment of advanced postmenopausal breast cancer. Possinger K; Jonat W; Höffken K Ann Oncol; 1994; 5 Suppl 7():S7-10. PubMed ID: 7873464 [TBL] [Abstract][Full Text] [Related]
22. [Clinical trial of lentaron for postmenopausal patients with advanced breast cancer]. Liu X; Song S; Jiang Z; Wu S; Yu J; Wang T Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):511-3. PubMed ID: 12485513 [TBL] [Abstract][Full Text] [Related]
23. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer. Noberasco C; Bajetta E; Zilembo N; Di Leo A; Cappuzzo F; Bartoli C; Bono A; Bichisao E Oncology; 1995; 52(6):454-7. PubMed ID: 7478430 [TBL] [Abstract][Full Text] [Related]
24. Pilot study of formestane in postmenopausal women with breast cancer. Joseph JK; Lim AK Med J Malaysia; 1998 Mar; 53(1):37-41. PubMed ID: 10968135 [TBL] [Abstract][Full Text] [Related]
25. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer. Michaud LB; Buzdar AU Drug Saf; 1999 Oct; 21(4):297-309. PubMed ID: 10514021 [TBL] [Abstract][Full Text] [Related]
26. Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer. Iwase H; Yamamoto Y Int J Clin Oncol; 2015 Apr; 20(2):253-61. PubMed ID: 25673474 [TBL] [Abstract][Full Text] [Related]
27. Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. Rose C; Kamby C; Mouridsen HT; Andersson M; Bastholt L; Møller KA; Andersen J; Munkholm P; Dombernowsky P; Christensen IJ Breast Cancer Res Treat; 2000 May; 61(2):103-10. PubMed ID: 10942095 [TBL] [Abstract][Full Text] [Related]
28. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women. Buzdar AU; Vergote I; Sainsbury R Breast J; 2004; 10(3):211-7. PubMed ID: 15125747 [TBL] [Abstract][Full Text] [Related]
29. Historical perspective on hormonal therapy of advanced breast cancer. Jordan C Clin Ther; 2002; 24 Suppl A():A3-16. PubMed ID: 11911507 [TBL] [Abstract][Full Text] [Related]
30. Aromatase inhibition: basic concepts, and the pharmacodynamics of formestane. Dowsett M Ann Oncol; 1994; 5 Suppl 7():S3-5. PubMed ID: 7873460 [TBL] [Abstract][Full Text] [Related]
31. The influence of endocrine treatments for breast cancer on health-related quality of life. Buijs C; de Vries EG; Mourits MJ; Willemse PH Cancer Treat Rev; 2008 Nov; 34(7):640-55. PubMed ID: 18514425 [TBL] [Abstract][Full Text] [Related]
32. A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group. Bajetta E; Zilembo N; Barni S; Noberasco C; Martinetti A; Ferrari L; Schieppati G; Buzzoni R; Jirillo A; Amichetti M; D'Aprile M; Comella G; Bichisao E; Bolelli GF; Attili A; Bombardieri E Ann Oncol; 1997 Jul; 8(7):649-54. PubMed ID: 9296217 [TBL] [Abstract][Full Text] [Related]
33. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763 [TBL] [Abstract][Full Text] [Related]
34. Emerging role of aromatase inhibitors in the treatment of breast cancer. Harvey HA Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):32-5. PubMed ID: 9556789 [TBL] [Abstract][Full Text] [Related]
35. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients. Zilembo N; Bajetta E; Bichisao E; Martinetti A; La Torre I; Bidoli P; Longarini R; Portale T; Seregni E; Bombardieri E Biomed Pharmacother; 2004 May; 58(4):255-9. PubMed ID: 15183852 [TBL] [Abstract][Full Text] [Related]
36. Endocrine treatment of advanced breast cancer. Dowsett M Acta Oncol; 1996; 35 Suppl 5():68-72. PubMed ID: 9142970 [TBL] [Abstract][Full Text] [Related]
37. Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer. Wiseman LR; McTavish D Drugs; 1993 Jan; 45(1):66-84. PubMed ID: 7680986 [TBL] [Abstract][Full Text] [Related]
38. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341 [TBL] [Abstract][Full Text] [Related]
39. Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors. Goss PE; Strasser K Drugs; 2002; 62(6):957-66. PubMed ID: 11929341 [TBL] [Abstract][Full Text] [Related]
40. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Miller WR; Dixon JM Cancer Control; 2002; 9(2 Suppl):9-15. PubMed ID: 11965226 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]